产品/疗法

复发性/难治性多发性骨髓瘤伴髓外浆细胞瘤在疾病晚期成功再挑战人源化 B 细胞成熟抗原靶向 CAR-T 细胞免疫治疗：一例病例报告

Relapsed/refractory multiple myeloma with extramedullary plasmacytomas successfully rechallenged with humanized B-cell maturation antigen-directed chi

四种已获批 CAR-T 细胞疗法治疗多发性骨髓瘤的疗效与安全性比较

Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T-Cell Therapies in Multiple Myeloma.

BCMA 靶向 CAR-T 治疗复发/难治性多发性骨髓瘤长期结局的关键预测因素

Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma.

BCMA CAR-T 治疗在部分 r/r MM 患者中可提供持久缓解。早期干预可能通过促进持续 MRD 阴性来改善患者预后，从而改善整体治疗结局。

一线抗 BCMA CAR-T 细胞治疗伴双克隆丙种球蛋白病和巨大浆细胞瘤的多发性骨髓瘤且合并多种合并症的虚弱患者：病例报告

First-line anti-BCMA CAR-T cell therapy in a fragile patient with biclonal gammopathy and giant plasma cell tumor multiple myeloma with multiple comor

一线抗 BCMA CAR-T 细胞疗法对高危 MM 患者有效且安全，即使对合并多种基础疾病的虚弱患者也是如此。

Equecabtagene Autoleucel 治疗复发/难治性多发性骨髓瘤患者：FUMANBA-1 非随机临床试验

Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical Trial.

在这项试验中，eque-cel 使接受过多线治疗的复发/难治性多发性骨髓瘤（RRMM）患者获得早期、深度且持久的缓解，安全性特征可控。

复发/难治性多发性骨髓瘤临床实践中 CAR-T 细胞治疗管理与疗效评估的共识指南与推荐：国际骨髓瘤工作组免疫治疗委员会报告

Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice f

Equecabtagene Autoleucel：首次获批

Equecabtagene Autoleucel: First Approval.